Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Sanja Perkovic"'
Autor:
Sanja Perkovic, Sandra Basic-Kinda, Vladimir Gasparovic, Zeljko Krznaric, Jaksa Babel, Ivana Ilic, Igor Aurer, Drago Batinic
Publikováno v:
Hematology Reports, Vol 4, Iss 3, Pp e16-e16 (2012)
Aggressive natural killer-cell leukaemia (ANKL) is a rare type of disease with fulminant course and poor outcome. The disease is more prevalent among Asians than in other ethnic groups and shows strong association with Epstein-Barr virus (EBV) and P-
Externí odkaz:
https://doaj.org/article/3bb95d01adf4443b8e983f42977ea6eb
Autor:
Mirna Golemovic, R. Serventi Seiwerth, Ines Bojanić, Sanja Perkovic, Sanja Mazić, Drago Batinić, B. Golubic Cepulic, Boris Labar, Fini Plenković, M. Lukic, Mirela Raos, Klara Dubravčić
Publikováno v:
Scopus-Elsevier
Extracorporeal photochemotherapy (ECP) is an immunomodulatory therapy which has been used in treatment of chronic GVHD (cGVHD).ECP involves separation of the mononuclear cells (MNC)with leukapheresis, followed by ex vivo administration of a photosens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c8618c1300acf4018a6297ca2cb0b87
https://www.bib.irb.hr/673060
https://www.bib.irb.hr/673060
Autor:
Sanja Perkovic, Drago Batinić, Dominik Lozić, Sandra Bašić-Kinda, Antica Duletić-Načinović, Ivo Ugrina, Igor Aurer
Composite mature B-cell lymphoproliferative neoplasms are rare entities characterized by the simultaneous presence of two or more distinctive B-cell derived monoclonal malignancies. This retrospective study used multiparametric flow cytometric analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45eda81c211b8e02943808fcaddfef58
https://doi.org/10.1007/s12185-013-1432-7
https://doi.org/10.1007/s12185-013-1432-7
Autor:
Sandra Bašić-Kinda, Dubravka Sertić, Sanja Perkovic, Boris Labar, Dragana Šegulja, Damir Nemet, Klara Dubravčić, Drago Batinić, Josip Batinić, Ivo Radman, Zinaida Peric, Lidija Volaric, Danica Matišić
Publikováno v:
Blood. 124:2050-2050
Objectives: To evaluate the clinical utility of the novel heavy/light chain immunoassay for the assessment of multiple myeloma patients. Methods: Serum samples of 99 multiple myeloma patients in different disease stages (74 IgG, 25 IgA) were analysed